A narrative review mapped the existing evidence for candidate treatments for long-term COVID, preferred by clinicians and experienced patients. The study used pragmatic methods including iterative stakeholder decision-making, monthly updated searches and prioritization surveys. They selected 14 top interventions: low-dose naltrexone, antivirals, metformin, nicotine, vagus nerve stimulation, antihistamines, guanfacine, colchicine, nattokinase, intravenous immunoglobulins, monoclonal antibodies, coenzyme Q10, multicomponent rehabilitation packages, and exercise rehabilitation packages. Six of these had evidence from randomized controlled trials specific to COVID: exercise (16 RCTs), coenzyme packs (2 RCTs), antivirals (1 RCT), vagus nerve stimulation (1 pilot RCT) and monoclonal antibodies (1 small RCT). The remaining interventions relied on indirect or very low-certainty data. The certainty of evidence was mostly low to very low across interventions, and safety with feasibility varied. There is insufficient direct evidence for clinical recommendations; the proposed treatments are suitable for rigorous testing in future studies for their biological plausibility, feasibility, and acceptability.